BV6 is a small molecule inhibitor that functions as an antagonist of inhibitor of apoptosis proteins (IAPs), particularly cIAP1, cIAP2, and XIAP. It is widely used in cancer research due to its ability to induce apoptosis in tumor cells. By blocking IAPs, BV6 promotes caspase activation and sensitizes cancer cells to death receptor-mediated apoptosis, especially in combination with agents like TNFα or TRAIL. It has shown efficacy in preclinical models against various cancers, including leukemia, glioblastoma, and solid tumors. Additionally, BV7 enhances the effects of chemotherapy and radiation, making it a potential candidate for combination therapies. Its role in overcoming treatment resistance is a key focus in oncology drug development.